Johnson & Johnson (JNJ)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 35,153,000 | 34,624,000 | 13,054,000 | 12,724,000 | 17,941,000 | 19,157,000 | 18,366,000 | 19,830,000 | 20,878,000 | 17,880,000 | 17,767,000 | 15,115,000 | 14,714,000 | 16,986,000 | 15,185,000 | 17,166,000 | 15,119,000 | 14,151,000 | 16,332,000 | 14,679,000 |
| Total stockholders’ equity | US$ in thousands | 68,774,000 | 71,228,000 | 75,149,000 | 70,869,000 | 76,804,000 | 74,599,000 | 76,357,000 | 74,709,000 | 74,023,000 | 70,272,000 | 69,580,000 | 65,834,000 | 63,278,000 | 64,473,000 | 62,978,000 | 61,294,000 | 59,471,000 | 58,210,000 | 60,785,000 | 58,955,000 |
| ROE | 51.11% | 48.61% | 17.37% | 17.95% | 23.36% | 25.68% | 24.05% | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $35,153,000K ÷ $68,774,000K
= 51.11%
Johnson & Johnson's return on equity (ROE) has shown fluctuations over the past eight quarters. In Q4 2023, the ROE was 51.11%, indicating a strong performance in generating profits from shareholders' equity. This was an increase from the previous quarter's ROE of 48.61%.
However, the ROE in Q2 and Q1 2023 stood at 17.37% and 17.95% respectively, reflecting a significant decline from the previous quarters. These lower ROE figures suggest that the company may not have been as efficient in utilizing shareholders' equity to generate profits during that period.
Comparing the most recent ROE with the same quarter of the previous year, there has been notable improvement as Q4 2022 had an ROE of 23.36%. Overall, Johnson & Johnson's ROE has shown variability over the past two years, but the recent increase to 51.11% in Q4 2023 indicates a strong performance in generating returns for shareholders.
Peer comparison
Dec 31, 2023